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Abstract 
 Recent studies indicate that eculizumab is often given in excess to aHUS patients. 
Individualization of treatment is thus highly requested, however, data on pharmacokinetics 
and pharmacodynamics of eculizumab remain limited. We analyzed 11 patients during  
induction (weekly), maintenance (2-weekly) and tapering (every 3-8 weeks) phases of 
treatment. 
The trough eculizumab levels increased with each additional dose during the 
induction phase (depending on body weight). During maintenance, high eculizumab 
concentrations of up to 772 µg/mL were observed. The levels decreased with each following 
dose during tapering (3- and 4-week intervals), however three patients maintained target 
eculizumab levels over long time periods (30-48 weeks). At intervals of 6-8 weeks target 
eculizumab levels were no longer attained. Serum samples with eculizumab concentrations 
≥50 µg/mL showed adequate complement blockade. 
Our data provide essential insight for optimization of eculizumab dosing schemes and 
lessening of therapy burden for the patients and cost of the treatment.  
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 Introduction 
Hemolytic uremic syndrome (HUS) is a severe form of thrombotic microangiopathy 
(TMA) characterized by hemolytic anemia, thrombocytopenia and acute renal failure. The 
majority of cases are caused by an infection with Shiga toxin producing Escherichia coli 
(STEC). However, 5-10% of HUS occurs without a preceding STEC infection and is 
attributed to complement dysregulation [1-6]. Currently, alternative complement pathway 
aberrations are identified in 50-60% of atypical HUS (aHUS) patients. Genetic variants 
affecting complement factor H (CFH), complement factor I (CFI), membrane co-factor protein 
(CD46), C3, complement factor B and thrombomodulin as well as autoantibodies against 
CFH (anti-CFH) are associated with aHUS pathogenesis [7-19]. More recently, genetic 
rearrangements resulting in CFH/CFH-related hybrid proteins have also been described [20-
22]. 
Eculizumab is a humanized monoclonal complement inhibitor that binds to C5 and 
prevents its cleavage and activation into C5a and C5b, blocking formation of the terminal 
complement complex C5b-9. Eculizumab is currently approved by the Food and Drug 
Administration and European Medicines Agency (EMA) for the treatment aHUS and has 
proven to be highly efficient in the treatment of this disease [5, 23-27]. The current 
international guidelines recommend life-long treatment with eculizumab. However, the 
resulting life-long complement blockade may increase the risk of meningococcal infection, 
and eculizumab treatment is associated with extreme costs [28, 29].  There are no studies 
that would support the necessity of a life-long treatment in all aHUS patients. Before 
eculizumab has become available, plasma therapy was a main-stream approach for the 
treatment of aHUS. The guidelines for plasma therapy in aHUS advised individualized 
regimen and withdrawal in patients that have reached remission [30, 31]. Therefore, many 
nephrologists use a restrictive approach for eculizumab treatment in aHUS and discontinue 
therapy when patients reach remission [32-39]. A subset of patients that discontinued 
eculizumab in these reports experienced relapse, and the therapy had to be reinitiated. This 
underscores the need for close monitoring of these patients for signs of relapse. 
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The recommended concentrations of eculizumab for efficient complement blockade 
are 50-100 µg/ml, however in the past our and other studies demonstrated that eculizumab 
levels in patients, that receive the drug every two weeks exceed this reference by up to ten 
fold [32, 40-42]. Thus, optimization of dosing regimen in eculizumab therapy is urgently 
needed, however, pharmacokinetic and pharmacodynamic data to guide such personalized 
treatment schemes remain limited.  
In this study, we followed patients who were treated with standard and extended 
infusion intervals, and analyzed eculizumab concentrations and complement blockade in 
these patients. 
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Results 
Patient cohort 
In total, five pediatric and six adult patients diagnosed with aHUS treated with 
eculizumab were included in this study (Table 1). In nine of these patients, pathogenic 
variations in the complement genes were found. One aHUS patient (P3) had anti-CFH and in 
one other patient (P9) no genetic abnormalities or anti-CFH were detected. In nine patients, 
the intervals between eculizumab infusions were extended for up to eight weeks after stable 
remission was achieved. In one of these patients (P1), eculizumab treatment was 
discontinued completely. Serum samples of this patient were continuously collected through 
week 26 after the last eculizumab dose (Table 1), no disease recurrence was observed 
during the study period. In two patients, eculizumab treatment was discontinued without 
extension of dosage intervals beyond two weeks due to an allergic reaction (P8) and severe 
pneumonia (P11). 
 
Serum eculizumab concentrations in aHUS cohort 
The eculizumab trough concentrations (lowest drug concentration in blood between 
two consecutive infusions) that were measured in 11 patients are depicted in Figure 1A. The 
detected values were 36-459 µg/mL (n=27) and 40-772 µg/mL (n=90) during the induction 
and maintenance phases, respectively. During tapering, concentrations of 61-367 µg/mL 
(n=38), 11-256 µg/mL (n=38) and 13-161 µg/mL (n=6) were measured at 3- , 4- and 5- week 
infusion intervals. At intervals of 6-8 weeks (n=10), the concentrations were 0-41 µg/mL. For 
infusion intervals of 1-5 weeks, attainment of the minimal target level of 50 µg/mL was found 
in 75-91% of patients (Figure 1B). 
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Serum eculizumab concentrations in individual patients during infusions with 
standard and extended intervals  
In the induction phase, the eculizumab levels gradually increased with each following 
1-week interval by on average 73.1 (95% CI: 56.2-90.0) µg/mL, adjusted for body weight 
(Table 2). Two adult patients (P10 and P11) did not attain the target eculizumab level after the 
first infusion, but did so after the second dose (Figure 2A). Figure 3 shows that patients P10 
and P11 had the lowest trough eculizumab concentrations one week after the first 
eculizumab infusion and the highest sC5b-9 complex levels measured before the first 
infusion. The serum C5 levels in patients in acute phase before start of therapy were 52-136 
µg/mL, while values obtained from nine healthy controls were 80-107 µg/mL.  
Serum eculizumab concentrations did not change with each following dose at 2-week 
intervals (Figure 2B, Table 2), whereas the concentrations decreased on average by   -11.8 
(95% CI: -7.1- -16.6) µg/mL and -3.6 (95% CI: -1.1- -6.2) µg/mL with each following dose in 
the tapering phase of the 3- and 4-week intervals, respectively (Figure 2C and 2D, Table 2). 
However, only three patients had a follow-up with five or more infusions at 3- and 4-week 
intervals. At 3-week intervals, the eculizumab levels remained relatively high in P4 and 
within/slightly above the target range of 50-100 µg/mL throughout the observed periods of 10 
and 11 intervals (30 and 33 weeks) in P2 and P3, respectively. At 4-week intervals, the 
eculizumab levels remained within the recommended range throughout 12 intervals (48 
weeks) of therapy for P4 only.  
Body weight had a small effect on eculizumab level in the induction period only -3.9 
(95% CI: -1.8 - -6.0) µg/mL per kg, while age did not have an effect in any of the intervals. 
The number of available data points at 5-week intervals did not allow statistical 
analysis. However, four of the five patients analyzed still attained the eculizumab target 
concentration after the first 5-week interval and P10 also attained the target range after the 
second 5-week interval (Figure 2E). 
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Complement inhibition under eculizumab treatment  
All samples that were measured in our study and reached the eculizumab target level 
of 50 µg/mL had a CH50 value ≤ 12% (detection limit 10%) (Figure 4). 
 
This article is protected by copyright. All rights reserved.
8 
 
Discussion 
 In this report we, to our knowledge, for the first time performed a systematic analysis 
of eculizumab levels in patients, receiving the drug with various (standard and extended) 
infusion intervals. 
In the induction phase (1-week intervals) we have observed a weight-dependent 
increase in eculizumab concentration with each following infusion, which is consistent with 
the half-life of eculizumab in aHUS patients reported as 7.8-19.5 days [41], 
http://www.ema.europa.eu/ema/. In two patients with high initial sC5b-9 levels, the values 
were below the target range one week after the first infusion. Previous report investigating 
efficacy of eculizumab treatment in patients with TMA after hematopoietic stem cell 
transplantation indicated that patients with higher levels of sC5b-9 complex before treatment 
have faster initial eculizumab clearance [43]. Interestingly, recent study indicated that 
eculizumab is able to bind to sC5b-9 in vitro, which suggests that part of the drug may be 
scavenged into a complex with sC5b-9 at first infusion [42]. Elevated sC5b-9 is a known 
biomarker in aHUS and thus should be taken into consideration in design of future 
personalized eculizumab protocols [44, 45]. 
In the maintenance phase (2-week intervals) the levels of eculizumab had reached 
extremely high values of up to 772 µg/mL. Considerable excess of eculizumab in patients 
was also previously reported by our and other studies [32, 40-42]. Interestingly, one of the 
patients (P11) who had a severe pneumonia did not attain minimal target value of eculizumab 
and complete complement inhibition at the second infusion at 2-week interval. The reason of 
this is not clear, however, since levels of sC5b-9 have been shown to influence eculizumab 
pharmacokinetics, inflammation and increased rate of complement activation may have 
caused lower eculizumab concentration in this patient.  
Although most patients attain eculizumab levels far above the recommended range at 
2-week intervals, P11 illustrates that in some patients with ongoing active disease standard 
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eculizumab dosing may be not sufficient for complement blockade and this should be taken 
into consideration when applying extended eculizumab regimen.  
Interestingly, P11 developed severe pneumonia while having sub-therapeutic 
eculizumab levels. Although it was not a meningococcal infection, for which the terminal 
complement pathway is especially important, this case emphasizes the need to evaluate how 
much of residual complement activity is necessary to decrease risk of infection and how 
much of this activity may be safely allowed without risk of an aHUS relapse. 
No significant correlation between eculizumab levels and number of received 
infusions was observed in the maintenance phase. Previously in another study, weight of the 
patient was correlated to the median trough concentration in a small group of aHUS patients 
(n=7), which was not reproduced in our study [41]. Nevertheless, with the exception for P11, 
all other patients attained target eculizumab levels at all 2-week infusion intervals that were 
analyzed.   
During tapering of the treatment with extended intervals of 3- and 4- weeks, 
statistically significant decrease in eculizumab concentration was observed with each 
infusion. This indicates, that complement blockade may remain adequate at the first infusions 
of the extended intervals, but diminish overtime.  
However, at 3-week interval, in two patients (P2, P3) eculizumab recommended range 
of 50-100 µg/mL was attained and complement was efficiently blocked throughout the 
observed period of 10 and 11 intervals (30 and 33 weeks), respectively. At 4-week interval for 
one other patient (P4), the eculizumab levels remained within the recommended range and 
complement was completely blocked throughout 12 intervals (48 weeks) of therapy. 
Interestingly, of the three pediatric patients, who were able to sustain optimal eculizumab 
concentration in extended intervals, two (P3, P4) were treated with a standard adult dosage 
(1200 mg) and one (P2) with standard pediatric dosage (300 mg) per infusion based on their 
body weight (Table 1). These three cases illustrate how monitoring of eculizumab 
concentrations and complement inhibition allows to establish optimal infusion intervals which 
can be maintained over a long period of time for patients on adult and pediatric regimen.  
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Furthermore, our data indicate that at 5-week intervals attainment of target 
eculizumab range is possible at least for one or two infusions.  
Overall, quite high inter-patient variability has been observed. In our manuscript we 
analyzed influence of body weight and age on the eculizumab levels in individual patients. 
Moreover, levels of the sC5b-9 complex may play a role in eculizumab clearance after the 
first eculizumab infusion and may contribute to variability. To facilitate individualized 
treatment options, inter-patient variability should be investigated further in the future.  
Our findings suggest that C5 concentrations vary considerably among the patients, 
more than among the controls. Our previous data using C5 deficient serum indicated that 
even a 1-2% of unblocked C5 in serum may already lead to measurable complement activity 
[32]. Thus, when fine-tuning the eculizumab therapy based on patient’s needs, C5 
concentration may be important to take into account. 
In our previous work, we measured eculizumab-C5 complexes in patients, which in 
the situation of substantial eculizumab excess, as was observed in that study, provided a 
good indication of C5 levels. The data indicated some fluctuation of eculizumab-C5 
complexes [32] during the course of therapy. Relevance of these findings for personalized 
treatment should be investigated further. 
In this study only dosing intervals have been varied. However, in the future also 
options for the adjustment of the administered eculizumab dosage should be investigated. To 
this end, proportionality across the recommended dosing range of 50-100 µg/mL should be 
addressed at various diseases stages. Current knowledge on pharmacokinetics and 
pharmacodynamics indicates that eculizumab is bound to C5 and sC5b-9 in vitro [42]. In vivo 
deposition on other ligands, including surface of blood cells, endothelium, etc. is also 
possible. It may interfere with drug’s complement inhibiting activity and thus should be taken 
into account when lowering the treatment dose. 
In this study three samples with 93-250 µg/mL of eculizumab and residual 11-12% 
activity in CH50 assay were observed (Figure 4). These findings are in line with previous 
work, where the authors also observed several samples with eculizumab >99 µg/mL (which 
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they use as a target reference) and CH50 >10 % [43]. Interestingly, recent data point out that 
eculizumab inhibition of complement may not always be complete and even high drug levels 
would not always completely block complement in an in vitro assay [46]. Clinical importance 
of such residual complement activity in aHUS should be further investigated. 
Thus, in this study we performed a thorough analysis of data of patients who were 
treated with eculizumab and where standard and extended intervals between infusions were 
applied. Our data indicate that eculizumab accumulates in the body  during 1-week intervals 
(depending on the body weight and possibly initial sC5b-9 concentration) remains stable at 
2-week intervals, and diminishes during 3- and 4- week intervals. Importantly, extended 3- 
and 4- week intervals may be optimal for complete complement inhibition in a considerable 
subset of pediatric and adult patients, as shown in this study. Our data indicate that even at 
5-week intervals at least some of the patients were able to sustain optimal eculizumab 
concentration and complement inhibition, at least for a short time. As our study included a 
relatively limited number of patients, further optimization of treatment intervals in aHUS 
should be evaluated in a larger patient cohort.  
The results of this study have laid the base to formulate the Dutch guideline for the 
restrictive treatment regimen of aHUS patients that is currently being introduced in the 
Netherlands. In the future, it will help to design correct individualized dosing schemes for 
patients in acute aHUS that require continuous complement blockade, as well as for patients 
in remission for whom therapy is being discontinued by using gradual extension of intervals. 
That will help to save costs and make this efficient medication more accessible to the 
patients.  
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Methods 
Patient cohort 
The 11 patients, described in this study were diagnosed with aHUS and received 
treatment at the Radboud university medical center, Nijmegen, The Netherlands. Eculizumab 
was administered in the dosages that are recommended by the current EMA guidelines 
(http://www.ema.europa.eu/ema/). The current treatment schedule is split into two phases: 
the initial phase (weekly infusions for up to 4 weeks for patients ≥40 kg body weight), 
followed by the maintenance phase (life-long infusions every two weeks). For pediatric 
patients (<18 years old, <40 kg), the dosage regimen is adjusted to body weight. The other 
patients (pediatric and adult) receive the drug according to the schedule for adults.  
In this report, in patients who have reached remission (normalized hematological 
parameters and improved/stable renal function), the therapy was reevaluated and intervals 
between infusions were gradually extended (while keeping maintenance infusion doses 
unchanged) or therapy was discontinued (Table 1). In two patients, eculizumab treatment 
was discontinued without extension of dosage intervals beyond two weeks due to an allergic 
reaction (patient 8 (P8)) and severe pneumonia (P11). In nine patients ≥40 kg, the 
eculizumab dose was 1200 mg in the maintenance/tapering phase and for the two children 
with body weight of 15 kg (P2) and 11 kg (P9), the dose was 300 mg. 
 During tapering/discontinuation of therapy, all patients and/or their caregivers were 
strictly instructed to contact their physician in case of any signs of infections, generalized 
malaise, fever, hematuria, edema, oliguria, paleness or other signs indicating recurrence of 
aHUS. In case of signs of aHUS recurrence (which did not take place during the described 
period), eculizumab would be restarted immediately. 
Collection of blood samples 
Blood samples from healthy adult controls and patients just before each eculizumab 
infusion were collected and placed immediately on ice (ethylenediamineteraacetic acid 
(EDTA) blood) or allowed to clot for 30-40 minutes (min) at room temperature (whole blood). 
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EDTA plasma and serum samples were collected by centrifugation (10 min, 2000 x g, 4°C), 
aliquoted and stored at -80°C.  
 
Assay for detection of serum eculizumab concentration 
Eculizumab detection was performed using in-house enzyme-linked immunosorbent 
assay (ELISA). To capture eculizumab, 96-well plates (Greiner Microlon® 600 High Binding, 
Sigma-Aldrich, Zwijndrecht, The Netherlands) were coated with 0.5 µg/well of purified C5 
(Calbiochem®, San Diego, CA, USA) diluted in carbonate buffer (pH=9.6) overnight at 4˚C. 
The wells were washed with phosphate buffered saline (PBS) supplemented with 0.05% 
Tween-20 (PBST) (Sigma-Aldrich) after this and following steps. The plates were blocked 
with SuperBlock (PBS) Blocking Buffer (Thermo Fisher Scientific, Waltham, MA, USA) 30 
min at room temperature (RT) and then 45 min at RT with PBS, supplemented with 1% 
bovine serum albumin (PBS/BSA). Serum samples were diluted in PBS/BSA and dose 
response standards were prepared by adding eculizumab (Alexion Pharmaceuticals, 
Cheshire, CT, USA) to PBS/BSA. Samples and standards were added to the wells and 
incubated for 2 hours (h) at RT. Eculizumab detection was performed using incubation with 
Peroxidase AffiniPure Goat Anti-Human IgG (H+L) (Jackson ImmunoResearch Laboratories 
Inc., West Grove, PA, USA) diluted in PBST for 2 h at RT, o-phenylenediamine 
dihydrochloride tablets (Dako, Hevelee, Belgium) were added as a substrate. The reaction 
was stopped with 2M H2SO4, and samples were measured in a 96-well microtiter plate 
reader at 490 nm.  
Dilution linearity of the test was analyzed by measuring serum containing 383 µg/mL 
eculizumab and had coefficient of variation (CV) of 10.5% over the range of a standard 
curve. The detection limit of an assay was 8 µg/mL for undiluted samples. The assay showed 
variation coefficients of 2.9% (intra-assay, 352 µg/mL) and 5.2% (inter-assay, 328 µg/mL). 
Recovery was determined in 20 control samples spiked with 50 µg/mL (68 ± 31 %), 75 µg/mL 
(66 ± 25%)  and 150 µg/mL (74 ± 17%). 
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C5 assay 
 C5 concentrations were measured in available sera or EDTA plasma, that were 
collected from 10 aHUS patients in acute phase, before the start of eculizumab therapy and 
from nine healthy volunteers. The C5 levels were measured using Human Complement C5 
ELISA Kit (Abcam, Cambridge, UK), according to manufacturer’s instructions. 
Complement assays 
 The concentrations of fluid phase terminal C5b-9 complement complex (sC5b-9) in 
seven available EDTA plasma samples were quantified using ELISA, as previously described 
in detail by Bergseth et al. [47]. International complement standard 2 was used for 
quantification of sC5b-9 in complement activation units per mL (CAU/mL). 
Complement activity was accessed in serum samples by determining the activity of 
classical complement route (CH50) using an ELISA method adapted from [48]. Briefly, 
polyclonal goat (affinity purified) anti-human IgM (Cappel, Bioconnect Life Sciences, 
Huissen, The Netherlands) was coated in 96-wells plates (Nunc Maxisorb plates, Nunc, 
Roskilde, Denmark) at a concentration of 0.2 µg/well in carbonate buffer (pH 9.6), overnight 
at 4˚C. The plates were washed with Tris buffered saline (TBS) containing 0.05% Tween-20 
(TBST) after each step. Residual binding sites were blocked by incubation with 10 mM TBS 
containing 1% gelatin (BD Difco™, Franklin Lakes, New Jersey, USA) for 1 h at RT. After 
blocking, 0.25 µg/well  IgM (Fitzgerald Industries International, Acton, MA, USA) diluted in 
TBST was added and incubated for 1 h at RT. Next, standards (human pooled serum) and 
patient serum samples diluted in cold buffer containing 10 mM Tris, 84 mM NaCl, 0.5 mM 
MgCl2, 2 mM CaCl2 and 0.1% gelatin (pH 7.5), were added per well and incubated for 1 h at 
37˚C. Complement binding was detected using a monoclonal mouse-anti-human C5b-9 
antibody (Dako) diluted in TBST and incubated for 1 h at RT. After washing, alkaline 
phosphatase labeled goat anti-mouse IgG (Dako) in TBST was added for 1 h at RT. Alkaline 
phosphatase activity was revealed following incubation with 4-nitrophenyl phosphate 
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disodium salt hexahydrate as a substrate (Sigma-Aldrich). The reaction was stopped with 2 
M NaOH, and samples were measured in a 96-well microtiter plate reader at 450 nm.  
The reference value of CH50 of 67-149% was calculated with the results of 50 
healthy donors. 
 
Statistical analyses 
 GraphPad Prism 5 for Windows (GraphPad Software Inc., La Jolla, CA, USA) was 
used to plot eculizumab levels against treatment intervals, and sC5b-9 complex 
concentrations and CH50% against eculizumab levels.  
If a patient did not reach the minimal target level of 50 µg/mL eculizumab ≥ 1 time in a 
treatment interval, he/she was considered not to have attained the target level for that 
interval. Following, the percentages of patients not reaching the eculizumab target level were 
plotted against treatment interval.  
To evaluate changes in eculizumab concentrations by the number of infusions within 
a treatment interval, we used IBM Statistics 22.0 for Windows (IBM SPSS Inc., Chicago, IL, 
USA). For each treatment interval, we plotted eculizumab levels against infusion number and 
estimated the increase or decrease in eculizumab level per infusion with 95% confidence 
intervals (CI), using linear mixed models with infusion numbers as fixed and patients as 
random effects. Body weight (in kg) and age (in years) were included in these models as 
potential confounders.  
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Study highlights  
 
What is the current knowledge on the topic? 
Under the standard treatment regimen eculizumab levels in patients are very high. 
This increases the risk of side effects, such as meningococcal infection, and is 
associated with extremely high costs of the treatment. Pharmacokinetic and 
pharmacodynamic data to develop individualized eculizumab treatment schemes are 
limited. 
What question did this study address?  
Here we analyzed eculizumab serum concentrations in aHUS patients treated with 
standard and extended eculizumab infusion intervals. 
What this study adds to our knowledge?  
This is the first report analyzing eculizumab concentration in patients undergoing 
individualized treatment. 
How this might change clinical pharmacology or translational science? 
Our data provide essential insight for better optimization of eculizumab dosing 
schemes and lessening of therapy burden for the patients and costs of the treatment.  
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Figure legends 
Figure 1. Serum eculizumab concentrations in aHUS cohort. A. Eculizumab trough levels 
in 11 patients in the induction (weekly), maintenance (2-weekly) and tapering (every 3-8 
weeks) phases of therapy (Table 1). From one patient (P1), samples were also collected after 
discontinuation of treatment (at 14, 20, 26 weeks). The dashed lines indicate the 
recommended range of eculizumab levels of 50-100 µg/mL. B. Percentages of patients that 
attained the trough eculizumab level of 50 µg/mL in all measured samples in an interval are 
indicated in white, whereas percentages of patients with a value < 50 µg/mL in at least one 
sample are indicated in gray. Total numbers of patients analyzed for each interval are shown 
above the columns. 
Figure 2. Eculizumab concentrations in individual patients during infusions with 
standard and extended intervals. Eculizumab trough levels in 11 patients before next 
eculizumab infusion in the induction (1- week intervals, A), maintenance (2-week intervals, 
B) and tapering (3-, 4- and 5-week intervals, C, D and E) phases of therapy. The dashed 
lines indicate the recommended range of eculizumab levels of 50-100 µg/mL. Observed 
effects (*) of each following infusion or weight of a patient (kg) on eculizumab concentration 
as presented in Table 2 are indicated. 
Figure 3. sC5b-9 complex concentration at baseline and trough eculizumab levels after 
the first infusion. Seven patients (P1, P3, P4, P7, P9, P10, P11) of whom EDTA plasma 
was available were included. The dashed lines indicate the recommended range of 
eculizumab levels of 50-100 µg/mL. Patients that did not attain the recommended 
eculizumab level after first infusion are indicated (P10 and P11). 
Figure 4. Complement inhibition during eculizumab treatment in aHUS patients. 
Complement activity (CH50%) data of the samples included in the study are presented as 
percentage of activity of normal human pooled serum. The dashed lines indicate the 
recommended range of eculizumab levels of 50-100 µg/mL. 
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Patient aHUS pathogenic change 
 
Gender 
(F/M) 
Age at start 
of the 
observation 
(years) 
Body weight 
(kg) 
Studied dose 
intervals 
(weeks)1 
Total 
observation 
period (months) 
P1 CFH: c.1778T>A, p.Leu593Stop F 28 61 1-6, 8, 14, 20, 26 15.5 
P2 CFH: c.3572C>T (p.Ser1191Leu); 
CFH: c.3590T>C (p.Val1197Ala) 
M 2 15 2-4 24 
P3 Anti-CFH M 9 50 1-4 28.5 
P4 CFH/CFH1 hybrid protein  M 11 45 1-4 30.5 
P5 CFH: c.2572T>A (p.Trp858Arg) F 22 114 2-7 12 
P6 CFH: c.2120delC F 45 71 1-6 7 
P7 C3: c.481C>T (p.Arg161Trp) F 62 56 1-3, 8 8 
P82 C3: c.481C>T (p.Arg161Trp) F 11 46 1, 2 2.5 
P9 No changes found M 1.3 11 1-5 11.5 
P10 CFH: c.1520-1G>A (splice site) F 44 53 1-7 23.5 
P112 CFI: c.685T>C (p.Cys229Arg) F 21 85 1, 2 2 
 
1 All patients with body weight ≥ 40 kilo were treated with four weekly infusions of 900 mg at start of therapy, after that, starting from week 5 the 
patients were treated with 1200 mg. For P2 and P9 pediatric dosage was applied (600 mg infusion at first week, 300 mg at week 2 and further). 
Samples were taken after the indicated intervals since last eculizumab infusion.  
2 Eculizumab treatment in these patients was discontinued during the study due to allergic reaction (P8) and severe pneumonia (P11). 
 
Table 1. Characteristics of aHUS patients. 
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Table 2 Estimated effects of number of infusions on eculizumab concentration in serum per 
treatment interval. 
 
#  At the start of each interval, data were not collected from all patients 
& Adjusted for patient's body weight (kg); weight and age did not influence the other 
estimates.   
 
     
 
 
Number of 
patients in 
treatment 
interval# 
Range of 
samples 
per patient 
Estimated 
mean 
eculizumab 
level (µg/mL) 
 
95% CI 
 
1-week intervals      
At start of interval 7  131.1 53.6 208.6 
Increase/decrease per 
infusion 9 1 - 4 73.1
& 56.2 90.0 
      
 
2-week intervals      
At start of interval 10  271.9 176.9 366.9 
Increase/decrease per 
infusion 11 2 - 20 2.3 -0.7 5.3 
      
 
3-week intervals      
At start of interval 8  285.0 212.4 357.6 
Increase/decrease per 
infusion 9 1 - 9 -11.8 -16.6 -7.1 
      
 
4-week intervals      
At start of interval 6  158.2 80.8 235.6 
Increase/decrease per 
infusion 8 1 - 11 -3.6 -6.2 -1.1 
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